Start date: 01 July 2023
End date: 30 June 2028
ARTiDe aims to develop a new antigen-specific immunotherapy for type 1 diabetes, via genetic engineering, using patients' regulatory T lymphocytes (Treg) to express an autoreactive T lymphocyte receptor targeting an autoantigen relevant to this disease.
The aim is to be able to launch a phase I clinical trial at the end of the project.
Scientific coordinator of the project: Simon Fillatreau